About

Our mission is to make information easier to orient around: what is known, what remains uncertain, and where meaningful safety and policy questions belong. The main resource overview provides the starting point, while our organized information pathways help readers identify the topic area most relevant to their questions.

We do not present this material as a substitute for professional care, legal counsel, or individual decision-making. That boundary matters when information may be consequential, incomplete, or changing.

Information is reviewed against research literature, public registries, and official materials where appropriate. For example, study records can be checked through ClinicalTrials.gov study registrations, rather than relying only on summaries or informal accounts.

We also look for clear definitions and scope. The FDA’s drug safety information illustrates why safety communication benefits from careful qualification, source awareness, and attention to what a source does—and does not—establish.

• ✓Independence from clinic, provider, and treatment-center claims.
• ✓Plain language without flattening complexity.
• ✓Evidence awareness over promotional certainty.
• ✓Risk clarity and respect for context.

Those principles also shape how we reference adjacent public material: discussions connected to the Texas ibogaine bill context are treated as policy context, not legal advice, and material around drug addiction treatment claims is not presented as individualized treatment guidance.

Readers may encounter differing claims across jurisdictions and communities. References such as Canadian ibogaine context or accounts of an ibogaine trip experience can be part of the surrounding information environment, but they do not replace independently verified evidence or professional advice.

Likewise, content related to ibogaine plant seeds may raise questions that require careful source evaluation, awareness of applicable rules, and respect for the limits of a general information resource.